Shanghai-based United Imaging Healthcare (UIH, SHA: 688271) has reported impressive financial results for the year 2023, with revenues reaching RMB 11.411 billion (USD 1.57 billion), marking a 23.52% year-on-year (YOY) increase. Net profits for the period were recorded at RMB 1.974 billion (USD 270 million), up 19.21% YOY. The company’s commitment to research and development (R&D) was evident, with R&D expenses constituting 16.81% of its revenues, an increase of 0.94 percentage points from the same period in the previous year. By the end of 2023, UIH had launched nearly 120 products.
UIH has established partnerships with over 1,000 Class 3A hospitals, reinforcing its position in the medical imaging industry. Domestic operating revenue for the company reached RMB 9.73 billion, with PET/CT, PET/MR, and XR products leading the industry in 2023. Additionally, CT, MR, and RT products held top positions within the industry, while mid to high-end and ultra-high-end products experienced rapid growth and significant breakthroughs.
By the end of 2023, UIH had secured over 700 marketing approvals or quality management system certificates, including 45 products with CE marks and 44 with FDA 510(k) approvals. The company’s overseas operating revenue stood at RMB 1.68 billion, representing 14.70% of its total revenue, an increase from 11.74% in the same period of the previous year, with a notable uptick in sales of high-end equipment.- Flcube.com
